Abstract
Conflicting data exist regarding the relationship between Chlamydophila pneunoniae (C. pneumoniae) and hypertension. In this study, both C. pneumoniae IgG andIgA titresand Epstein–Barr virus antibody levels were measured in 146 sustained hypertensives defined by 24 h ambulatory blood pressure monitoring (ABPM) and 54 normotensives. C. pneumoniae antibodies were measured by microimmunofluorescence test. IgG⩾80 and IgA⩾40 were defined as elevated antibody titres. Epstein–Barr antibodies were measured in order to investigate whether a possible association exists between hypertension and other, similarly widespread in the general population, intracellular microorganisms. All participants underwent casual blood pressure (BP) readings and 24 h ABPM. Subjects having mean 24 h systolic/diastolic ambulatory BP>125/80 mmHg, with or without antihypertensive medication were defined as hypertensives. Controls were free of any history or clinical evidence of hypertension, cardiovascular or pulmonary disease. Of the total participants, 77 hypertensives (52.7%) and 10 normotensives (18.5%) had IgA titres ⩾40 (crosstabs P<0.000), whereas 76 hypertensives (52.1%) and 15 normotensives (27.8%) had IgG titres ⩾80, (crosstabs P<0.002). No difference was found in Epstein–Barr antibodies, between hypertensives and normotensives. In conclusion, C. pneumoniae, but not Epstein–Barr, antibody levels were found significantly higher in sustained hypertensives, suggesting high frequency of chronic C. pneumoniae, infections in this specific group of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grayston JT . Infection caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 5: 757–763.
Thom DH et al. Association of prior infection with C. pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68–72.
Mendall MA et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121–128.
Saikku P et al. Serological evidence of an association of a novel chlamydia TWAR with chronic coronary heart disease and acute myocardial infarctions. Lancet 1988; 2: 983–986.
Melnick LS et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study investigators. Am J Med 1993; 95: 499–504.
Grayston JT et al. Chlamydia pneumoniae (TWAR) in the atherosclerosis of carotid artery. Circulation 1995; 92: 3397–3400.
Wimmer MLJ, Sandmann SR, Saikku P, Haberl RL . Association of chlamydial infections with cerebrovascular disease. Stroke 1996; 67: 2207–2210.
Tavendale R et al. Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events; the Scottish Heart Health Study Cohort. Eur Heart J 2002; 23: 301–307.
Hirashima Y et al. Chlamydia pneumoniae infection is not involved in carotid artery stenosis. Artherosclerosis 2002; 163: 165–168.
Johnson W, Moses J, Kipshidze N . Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction. Cardiovasc Radiat Med 2001; 2: 221
Altman R, Rouvier J, Scazziota A, Gonzalez C . No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease. Inflammation 2002; 26: 25–30.
Danesh J et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 2002; 23: 371–375.
Cook PJ et al. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589–594.
Nishimura M et al. Inverse association of Chla-mydia pneumoniae infection with high blood pressure in Japanese adults. Am J Hypertens 2001; 14: 20–26.
Manning G, Rushton L, Millar-Craig MW . Clinical implications of white coat hypertension: an ambulatory blood pressure monitoring study. J Hum Hypertens 1999; 13: 817–822.
Pose-Reino A et al. Clinical implications of white coat hypertension. Blood Press 1996; 5: 264–273.
1999 World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
Zakopoulos NA et al. Reproducibility of ambulatory blood pressure measurements in essential hypertension. Blood Press Monit 2001; 6: 41–45.
Galimberti L . Uso adeguato ed inadeguato degli alcoolici in patologie e problemi connessi all' uso inadeguato degli alcoolici. Giunta Regionale Venice 1982; 10: 73–89.
Verdecchia P, Staessen JA, White WB, Imai Y, O’Brien ET . Properly defining white-coat hypertension. Eur Heart J 2000; 23: 106–109.
Jauhianinen T et al. Interference of immunoglobulin G antibodies in IgA antibody determinations for C. pneumoniae by microimmunofluorecence test. J Clin Microbiol 1994; 32: 839–840.
Bauer G . The rational basis for efficient Epstein–Barr virus (EBV) serology. Review. Clin Lab 1995; 41: 623–634.
Saikku P . The epidemiology and significance of Chla-mydia pneumoniae. J Infect 1992; 25 (Suppl 1) 27–34.
Kutlin A et al. Evaluation of Chalamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chalamydia pneumoniae infection. Clin Diag Lab Immunol 1997; 4: 213–216.
Hughes C et al. Possible nosocomial transmission of psittacosis. Infect Control Hosp Epidemiol 1997; 18: 165–168.
Ossewaarde JM, de Vries A, Bestebroer T, Angulo AF . Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chalamydia sp. strains. Appl Environ Microbiol 1996; 62: 328–331.
Verkooyen RP et al. Widely used commercially available Chlamydia pneumoniae antigen contaminated with mycoplasma. J Med Microbiol 1997; 46: 419–424.
Maass M et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998; 140 (Suppl 1) S25–S30.
Del Piano M, Sessa R, Di Pietro M . Chlamydia pneumoniae infection and atherosclerotic coronary disease: a new possible etiopathogenic association. In: Starling A (ed). Proceedings of the Third meeting of the European society for Chlamydia Research 1995 p225
Markus S et al. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832–837.
Saikku P . Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J 1999; 138 (Suppl 2) S500–S503.
Saikku P et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273–277.
Cook PJ, Davies P, Wise R, Honeybourne D . Chlamydia pneumoniae infection and ethnic origin. Ethn Health 1998; 3: 237–246.
Pristipino C et al. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101 (10)1102–1108.
Verdecchia P, Porcellati C, Schillaci G . Ambulatory blood pressure. An independent predictor of prognosis in essiential hypertension. Hypertension 1994; 24: 793–801.
Yamashiroya M, Ghosh L, Yang R, Robertson L . Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988; 130 (1) 71–79.
Benditt PE, Barrett T, McDougall KJ . Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983; 80: 6389–6389.
Musiani M et al. Antibody patterns against Cytomegalovirus and Epstein–Barr virus in human atherosclerosis. Microbiologica 1990; 13: 35–41.
Alexander ER, Harrison HR . Chlamydial infections. In: Evans AS, Brachman PS (eds). Bacterial Infections of Humans: Epidemiology and Control, 2nd edn. Plenum Medical Book Co: New York. 1991, pp 179–206.
Leinonen M, Saikku P . Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999; 138 (Supp 1): S504–S506.
Chapleau WM et al. Structural versus functional modulation of the arterial baroreflex. Hypertension 1995; 26: 341–347.
Vlachakis ND, Mendlowitz M, DGuia D, DGusman D . Diminished baroreceptors sensitivity in elderly hypertensives. Possible role of atherosclerosis. Atherosclerosis 1976; 24: 243–249.
Sanderson JE, Billingham JD, Floras J . Baroreceptor function in the hypertensive black African. Clin Exp Hypertens A 1983; 5: 339–351.
Li Z, Mao ZH, Abboud M, Chapleau WM . Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res 1996; 79: 802–811.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pitiriga, V., Kotsis, V., Alexandrou, ME. et al. Increased prevalence of Chlamydophila pneumoniae but not Epstein–Barr antibodies in essential hypertensives. J Hum Hypertens 17, 21–27 (2003). https://doi.org/10.1038/sj.jhh.1001501
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001501
Keywords
This article is cited by
-
Association of hypertension with infection and inflammation in a setting of disadvantage in rural India
Journal of Human Hypertension (2022)
-
Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain)
Journal of Human Hypertension (2005)